BioStock: Xintela’s strategy for 2023

2022 was an eventful and successful year for Xintela. The company entered into clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers and thus has two ongoing clinical phase I/IIa studies with XSTEM. In addition, further development of EQSTEM for the treatment of joint diseases in horses is planned. In parallel with the stem cell projects, a phase 0 study is being prepared in the subsidiary Targinta. Xintela’s CEO Evy Lundgren-Åkerlund tells us more about the plans for 2023 in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/xintelas-strategy-for-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se